MARKET COMPOSITE
VERU - Veru Inc6:18:46 PM 3/28/2024
Price
$0.74
+ 0.10 (15.22%)
Veru Inc., an oncology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care. The company's drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in Phase II clinical trial for the treatment of metastatic castration resistant prostate cancer, planned Phase IIb clinical trial for the treatment of taxane resistant metastatic triple negative breast cancer, and Phase II clinical trial for the treatment of COVID-19. Its drug candidates also include Zuclomiphene citrate, which has completed Phase II clinical trial for the treatment of hot flashes in men with advanced prostate cancer; VERU-100, a GnRH antagonist that is in planned Phase II clinical trial for the palliative treatment of advanced prostate cancer; Enobosarm, a selective androgen receptor agonist that is in planned Phase III registration study for the treatment of metastatic breast cancer; and TADFYN, a tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. Additionally, the company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Financials
Quarterly financials
(USD)Sep 2023Q/Q
Revenue3.9MM+16%
Gross Profit1.5MM+25%
Cost Of Revenue2.3MM+10%
Operating Income-10.8MM+38%
Operating Expenses13.4MM-3%
Net Income-10.8MM+62%
R&D6.6MM-
G&A6.8MM-38%
Amortization17K-6%
Interest Expense207.2K-68%
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    --Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it is rescheduling its 20

    MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator

    MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company’s non-complian

    MIAMI, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the formation of a new Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when com

    The heavy selling pressure might have exhausted for Veru Inc. (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript February 8, 2024 Veru Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Veru Inc. Investor Conference Call. [Operator Instructions] Please note, this […]

    Q1 2024 Veru Inc Earnings Call02-09-2024 03:19:02 AM

    Q1 2024 Veru Inc Earnings Call

    —Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone— —Company to initiate Phase 2b obesity study by April 2024— —Company completed public offering for net proceeds of $35.2 million, bringing total cash to $40.6 million at December 31, 2023— —Company to host conference call and webcast today at 8:00 a.m. ET— MIAMI, FL, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (N

    FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical function while augmenting fat loss in sarcopenic obese or overweight elderly patients on GLP-1 drug for weight loss Phase 2b clinical trial is expected to initiate by April 2024 Phase 2b clinical trial final topline

    The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.